Global Pulmonary Arterial Hypertension (PAH) Therapeutics Industry
NEW YORK, Aug. 30, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Pulmonary Arterial Hypertension (PAH) Therapeutics Industryhttp://www.reportlinker.com/p0960405/Global-Pulmonary-Arterial-Hypertension-PAH-Therapeutics-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
This report analyzes the worldwide markets for Pulmonary Arterial Hypertension (PAH) Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. European market for PAH Therapeutics is further analyzed by the following countries/regions - France, Germany, Italy, UK, Spain, and Rest of Europe. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 26 companies including many key and niche players such as Actelion Pharmaceuticals Ltd., Arena Pharmaceuticals, Inc., Bayer HealthCare Pharmaceuticals, Cipla Limited, Daiichi Sankyo Co., Ltd., Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline Plc, Nippon Shinyaku Co., Ltd., Pfizer, Inc., Sanofi S.A, The Novartis Group, United Therapeutics Corp., and YM BioSciences, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
To order this report:Therapy Industry: Global Pulmonary Arterial Hypertension (PAH) Therapeutics IndustryNicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article